EVOGENE LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 277.3 ILa | +3.97% |
|
+6.98% | -7.51% |
| Apr. 02 | Evogene Ltd. and The Kitchen FoodTech Hub Establishes Finally Foods Ltd | CI |
| Mar. 20 | Evogene Receives Minimum Bid Price Non-Compliance Notice From Nasdaq | MT |
| Sales 2024 * | 17M 6.32B | Sales 2025 * | 31.5M 11.72B | Capitalization | 37.69M 14.02B |
|---|---|---|---|---|---|
| Net income 2024 * | -20M -7.44B | Net income 2025 * | -17M -6.32B | EV / Sales 2024 * | 2.22 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.2 x |
| P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 142 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.34% |
More Fundamentals
* Assessed data
More news
Latest transcript on Evogene Ltd.
More press releases
| 1 day | +3.97% | ||
| 1 week | +6.98% | ||
| Current month | -1.53% | ||
| 1 month | -1.53% | ||
| 3 months | -1.25% | ||
| 6 months | +37.14% | ||
| Current year | -7.51% |
1 week
245.70
277.30
1 month
231.20290.00
Current year
231.20370.00
1 year
189.30610.40
3 years
189.301 466.00
5 years
189.303 350.00
10 years
189.306 067.00
| Managers | Title | Age | Since |
|---|---|---|---|
Ofer Haviv
CEO | Chief Executive Officer | 58 | 01-12-31 |
Yaron Eldad
DFI | Director of Finance/CFO | 57 | 22-03-31 |
Mark Kapel
CTO | Chief Tech/Sci/R&D Officer | 48 | 04-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Dan Falk
BRD | Director/Board Member | 79 | 21-11-16 |
Sarit Firon
CHM | Chairman | 58 | 16-08-10 |
Leon Recanati
BRD | Director/Board Member | 76 | 05-04-30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-02 | 277.3 | +3.97% | 203,934 |
| 24-05-01 | 266.7 | +6.59% | 40,153 |
| 24-04-30 | 250.2 | -1.92% | 60,719 |
| 24-04-25 | 255.1 | -1.58% | 9,122 |
Delayed Quote TEL AVIV STOCK EXCHANGE, May 02, 2024 at 10:31 am EDT
More quotes
Evogene Ltd is an Israel-based company, engaged in leveraging computational biology to design products for life-science-based industries including human health, agriculture, and industrial applications. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.
Calendar
2024-05-27
- Q1 2024 Earnings Release (Projected)
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -7.51% | 37.69M | |
| +26.28% | 48.09B | |
| -3.99% | 40.43B | |
| +46.62% | 40.62B | |
| -6.20% | 28.36B | |
| +6.36% | 24.89B | |
| -21.47% | 19.01B | |
| +27.58% | 12.09B | |
| -2.75% | 11.8B | |
| -2.02% | 11.88B |
- Stock Market
- Equities
- EVGN Stock
